Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNETIUM TC 99M SESTAMIBI.
Head-to-head clinical analysis: DRAXIMAGE MDP 25 versus TECHNETIUM TC 99M SESTAMIBI.
DRAXIMAGE MDP-25 vs TECHNETIUM TC 99M SESTAMIBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
Technetium Tc 99m sestamibi is a cationic lipophilic complex that passively diffuses across cell membranes and accumulates in mitochondria due to the negative mitochondrial membrane potential. It is used as a myocardial perfusion imaging agent to visualize blood flow to the heart muscle.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
Myocardial imaging: 740-1110 MBq (20-30 mCi) IV bolus, single dose. Parathyroid imaging: 740-925 MBq (20-25 mCi) IV bolus, single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Terminal elimination half-life: approximately 6 hours (range 4–8 hours) for myocardial clearance. Delayed clearance may occur in patients with hepatic or renal impairment.
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Primarily renal: approximately 33% of injected dose excreted in urine within 8 hours, increasing to about 50% by 24 hours. Hepatic uptake with subsequent biliary excretion accounts for the remainder; fecal elimination is less than 2% of administered dose.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical